🇺🇸 FDA
Pipeline program

GLA-SE

IDC-G100-2013-001

Phase 1 mab completed

Quick answer

GLA-SE for Merkel Cell Carcinoma is a Phase 1 program (mab) at Design Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Design Therapeutics
Indication
Merkel Cell Carcinoma
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials